FDA Grants Regular Approval to Sacituzumab Govitecan for TNBC

The FDA has granted a regular approval to sacituzumab govitecan for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have previously received 2 or more systemic therapies, at least 1 of them for metastatic disease.

Read the full article here

Related Articles